Definitions of Tuberculosis, Multidrug-Resistant TB (MDR TB) and Extensively Drug-Resistant TB (XDR TB)
View Drug-Resistant TB — A Visual Tour
An ancient disease, TB remains one of the major causes of disability and death worldwide. In 2006, 9.2 million new cases of TB emerged and TB killed 1.7 million people. NIAID is examining TB at its fundamental levels through research aimed at developing faster diagnostic tools, better vaccines, and shorter treatment times.
Multidrug-resistant and Extensively Drug-resistant Tuberculosis Research Agenda (PDF)
NIAID’s Role in Addressing Tuberculosis (TB), Drug-Resistant TB, and TB in People with HIV/AIDS
Workshop on the Involvement of Children in TB Drug Development - July 29, 2009
NIAID and Chinese Officials Sign Agreement to Foster TB Research in China’s Henan Province - April 28, 2009
NIAID TB Drug Screening Program Completes Compound Testing - April 21, 2009
Joint Statement on World TB Day—Mar. 24, 2009
NIAID Media Availability: Lab Tests Show Two-Drug Combination Effective Against Drug-Resistant TB Bacteria—Feb. 26, 2009
Plan to Combat Extensively Drug-Resistant Tuberculosis Recommendations of the Federal Tuberculosis Task Force—Feb. 12, 2009 (CDC)
All TB News Releases
Engineered Autophagy Boosts BCG Protective Immunity May Result in New Strategies for TB Vaccine Development. Read more.
Volunteer for NIAID-funded clinical studies related to tuberculosis on ClinicalTrials.gov.
Global Research, Africa
View a related publications including pamphlets, information sheets, and reports produced by NIAID for the general public on various health topics and research activities of NIAID.